Alan Tan, MD

Alan Tan, MD, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center and a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Articles

Improving Patient Communication and Treatment Decisions with ctDNA Monitoring in MIBC

December 8th 2025

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

Integrating ctDNA-Based MRD Testing in MIBC

December 8th 2025

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Unmet Needs and the Evolving Role of MRD Monitoring in MIBC

December 1st 2025

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Risk Stratification and Surveillance After

December 1st 2025

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Analyzing the Role of ctDNA and Adjuvant

November 20th 2025

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Biomarker, Diagnosis, and Evolving Treatment Paradigm in MIBC

November 20th 2025

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Advancements in Perioperative Therapy for MIBC

November 13th 2025

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Novel Neoadjuvant Therapies in MIBC

November 13th 2025

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Dr Tan on the Ongoing Investigation of Adaptive Treatment Intensification Strategies in RCC

August 1st 2025

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Dr Tan on the Rationale for Evaluating an Adaptive Immunotherapy Strategy in Previously Untreated RCC

August 1st 2025

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Dr Tan on Important Considerations for Nivolumab/Ipilimumab Selection in Metastatic ccRCC

June 17th 2025

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCC

January 11th 2025

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Dr Tan on the Role of Nivolumab/Ipilimumab in Favorable-Risk Advanced RCC

October 29th 2024

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

Dr Tan on the Selection of IO-Based Combination Regimens in Advanced RCC

October 28th 2024

Alan Tan, MD, discusses long-term data guiding the selection of immuno-oncology combination regimens in advanced renal cell carcinoma.

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

December 19th 2023

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Triple Combination Therapies in RCC: Clinical Trial Insights

December 19th 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

December 12th 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

December 12th 2023

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

December 5th 2023

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Sequencing and Second-Line Therapy in RCC: Patient Scenario

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.